Class II, Cleared on Substantial EquivalenceThin moat
Intuitive Surgical (ISRG) — moat facet
The route Intuitive used to reach the market is the route everyone behind it will use to follow.
Robotic surgical systems are regulated in the United States as Class II medical devices, and Intuitive describes the consequence without editorialising: its "current products are subject to premarket notification and clearance under section 510(k)", and to obtain it a manufacturer "must submit to the FDA a premarket notification submission" showing that the proposed device is substantially equivalent to a legally marketed predicate device1.
Class II sits in the middle of the FDA's three-tier structure — subject to general controls plus special controls such as performance standards, post-market surveillance, patient registries and guidance documents2, but not to the premarket approval process that governs the highest-risk devices.
For an incumbent this is a double-edged position. It made Intuitive's own path faster than a drug company's would have been, and it keeps the cost of each new indication manageable: the company has added clearances steadily across general, urologic, gynecologic, cardiothoracic and head-and-neck specialties3. It also means no regulator is protecting the franchise.
The real barrier is the indication-by-indication, country-by-country accumulation. Da Vinci 5 was cleared by the FDA in March 2024 for all specialties indicated for da Vinci Xi except cardiac and pediatric; South Korea followed in October 2024, Japan in June 2025, and European certification under the EU MDR in July 2025 — the last of those "excluding the use of force feedback", for which Intuitive intends to seek certification separately4.
That last detail is the shape of the whole thing: even Intuitive's own flagship reaches different markets with different capabilities at different times.
Judge this on the pace of new indications and geographies, which the company lists each year in its regulatory activities section. A slowing list would mean the accumulation had stopped compounding.
Medtronic cleared Hugo in December 2025 and Johnson & Johnson took a De Novo for Ottava in July 2026. The pathway Intuitive used is now demonstrably open to the two largest device companies in the industry.
The regulatory route that let Intuitive in has now let two rivals in. A margin that holds as they sell shows the clearance was never the moat; one that falls would show price concessions.
- ReportedRobotic surgical systems are regulated in the United States as Class II medical devices, and Intuitive describes the consequence without editorialising: its "current products are subject to premarket notification and clearance under...Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business: competition, intellectual property and government regulation (the fourteen named competitors, more than 5,600 patents in force and 2,500 pending, Class II devices cleared under section 510(k) on substantial equivalence, special controls, field actions and recalls) — FY2025 · publ. February 3, 2026 · source ↗
- ReportedClass II sits in the middle of the FDA's three-tier structure — subject to general controls plus special controls such as performance standards, post-market surveillance, patient registries and guidance documents, but not to the premarket...Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business: competition, intellectual property and government regulation (the fourteen named competitors, more than 5,600 patents in force and 2,500 pending, Class II devices cleared under section 510(k) on substantial equivalence, special controls, field actions and recalls) — FY2025 · publ. February 3, 2026 · source ↗
- ReportedIt made Intuitive's own path faster than a drug company's would have been, and it keeps the cost of each new indication manageable: the company has added clearances steadily across general, urologic, gynecologic, cardiothoracic and...Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business: competition, intellectual property and government regulation (the fourteen named competitors, more than 5,600 patents in force and 2,500 pending, Class II devices cleared under section 510(k) on substantial equivalence, special controls, field actions and recalls) — FY2025 · publ. February 3, 2026 · source ↗
- ReportedDa Vinci 5 was cleared by the FDA in March 2024 for all specialties indicated for da Vinci Xi except cardiac and pediatric; South Korea followed in October 2024, Japan in June 2025, and European certification under the EU MDR in July 2025...Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business (the da Vinci and Ion platforms, instruments with a use count enforced in the instrument itself, training pathways and SimNow, enabling technologies, manufacturing sites, employees by function, and the seasonality of benign procedures) — FY2025 · publ. February 3, 2026 · source ↗